MorphoSys AG with ticker code (MOR) now have 4 market analysts covering the stock. The analyst consensus now points to a rating of ‘Hold’. The range between the high target price and low target price is between 15.03 and 2.91 calculating the average target price we see $6.10. Given that the stocks previous close was at $5.17 this now indicates there is a potential upside of 18.0%. Also worth taking note is the 50 day moving average now sits at $4.46 and the 200 day moving average is $4.68. The market capitalization for the company is $723m. Company Website: https://www.morphosys.com
The potential market cap would be $853m based on the market consensus.
MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The company also develops Pelabresib, a small molecule to treat myelofibrosis; Felzartamab, an antibody directed against CD38 for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease; and CPI-0209, a small molecule to promote anti-tumor activity by inhibiting EZH2 and EZH1. In addition, it develops Gantenerumab, an antibody for the treatment of Alzheimer’s diseases; and Otilimab, an antibody for rheumatoid arthritis. The company has a regional licensing agreement with I-Mab Biopharma to develop and commercialize felzartamab in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma; a joint collaboration and license agreement with Incyte Corporation to develop and commercialize MorphoSys investigational compound tafasitamab; and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.
The company is not paying dividends at this time.
